Generic Name and Formulations:
Nitroglycerin 0.1mg/hr, 0.2mg/hr, 0.3mg/hr, 0.4mg/hr, 0.6mg/hr, 0.8mg/hr; transdermal patches.
Merck & Co., Inc.
Indications for NITRO-DUR:
Prophylaxis of angina. Not for acute attacks.
Initially one 0.2–0.4mg/hr patch for 12–14hr/day. Remove patch for 10–12hrs/day.
Concomitant PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil), riociguat.
Acute MI. Volume depletion. Hypotension. Heart failure. Hypertrophic cardiomyopathy. Reduce dose if hypotension occurs. Remove before defibrillation or cardioversion. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with PDE-5 inhibitors, riociguat. Hypotension potentiated with alcohol, other vasodilators, calcium channel blockers.
Headache, increased angina, lightheadedness, syncope, orthostatic hypotension, tachycardia, rash.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Short Forms of Parent General Behavior Inventory Reliable at Identifying Youth Mood Symptoms
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Digital Media Engagement Associated With ADHD Symptoms in Adolescents
- Strong Social Networks May Mitigate the Effects of Childhood Adversity
- Unexpected Effect of Substance Use Disorders on Recovery From Bipolar Depression
- Republican Opposition to Obamacare: What's Done, What's to Come
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Integrating Treatments for Opioid Use Disorder and Infectious Diseases